8-K: Tenon Medical Announces Warrant Exercise Inducement Offer, Aims to Raise $3 Million

Tenon Medical, Inc. is offering new warrants to a holder of existing warrants to incentivize the exercise of those warrants at a reduced price, potentially generating $3 million in gross proceeds.

Summary

• Tenon Medical, Inc. has entered into a warrant exercise inducement offer with a holder of existing common stock purchase warrants.
• The holder can exercise warrants for up to 2,445,700 shares at a reduced price of $1.25 per share.
• In exchange for exercising the existing warrants, the company will issue new unregistered warrants to the holder.
• These include Series C-1 warrants to purchase up to 2,445,700 shares and Series C-2 warrants to purchase up to 1,222,850 shares, both at an exercise price of $1.25 per share.
• The new warrants are not exercisable without stockholder approval, which the company must seek within 165 days.
• If all existing warrants are exercised, Tenon Medical expects to receive approximately $3 million in gross proceeds.
• The company intends to use the net proceeds for working capital and general corporate purposes.
• Tenon Medical has engaged A.G.P./Alliance Global Partners as its financial advisor for this transaction, paying them a 7% cash fee on the gross proceeds and reimbursing up to $40,000 in legal expenses.
• The company will file a registration statement for the resale of shares issuable upon exercise of the new warrants within 30 days and aims to have it effective within 60-90 days.
• For 60 days after the resale registration statement is effective, the company has agreed to restrictions on issuing further common stock or equivalents.
• For six months commencing March 12, 2025, the Company is also prohibited from entering into any agreement to issue Common Stock or Common Stock equivalents involving a Variable Rate Transaction.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the company is raising capital, it involves dilution and restrictions on future issuances. The success depends on warrant holder participation and stockholder approval.

Positives

• The company could receive $3 million in gross proceeds, strengthening its working capital.
• The inducement offer encourages warrant holders to exercise their warrants, potentially increasing the number of outstanding shares and liquidity.
• The company intends to use the net proceeds for working capital and general corporate purposes.
• The company has engaged a financial advisor to assist with the transaction.

Negatives

• The new warrants are not exercisable without stockholder approval, which introduces uncertainty.
• The company is paying a 7% cash fee to the financial advisor, which reduces the net proceeds.
• The company has agreed to restrictions on issuing further common stock or equivalents for a period following the effectiveness of the resale registration statement, which could limit its flexibility.
• The company is prohibited from entering into any agreement to issue Common Stock or Common Stock equivalents involving a Variable Rate Transaction for a six-month period commencing on March 12, 2025.

Risks

• Stockholder approval for the new warrants may not be obtained.
• The warrant holder may not exercise all of the existing warrants, resulting in less than $3 million in gross proceeds.
• The resale registration statement may not become effective within the expected timeframe.
• The restrictions on issuing further common stock or equivalents could limit the company's financial flexibility.
• The company is prohibited from entering into any agreement to issue Common Stock or Common Stock equivalents involving a Variable Rate Transaction for a six-month period commencing on March 12, 2025.

Future Outlook

The company intends to use the net proceeds for working capital and general corporate purposes and aims to have the resale registration statement effective within 60-90 days.

Management Comments

• Tenon Medical, Inc. (the Company) is pleased to offer (this Inducement Offer) to you (Holder, you or similar terminology) the opportunity to receive new warrants to purchase up to a number of shares (the New Warrant Shares) of Common Stock, par value $0.0001 per share (the Common Stock), equal to 150% of the number of shares of Common Stock issuable to you pursuant to the exercise of that certain Common Warrant to Purchase Shares of Common Stock issued to you on September 16, 2024 (Existing September 2024 Common Warrants or the Existing Common Warrants), as more particularly set forth on the signature page hereto, in consideration for exercising for cash any or all such Existing Common Warrants.

Industry Context

Warrant inducement offers are a common strategy for companies to raise capital by incentivizing existing warrant holders to exercise their warrants, often at a reduced price.

Comparison to Industry Standards

• Similar warrant inducement offers have been used by companies like Titan Machinery Inc. and FuelCell Energy Inc. to raise capital.
• The financial advisory fee of 7% is within the typical range for similar transactions, although the specific percentage can vary based on the size and complexity of the deal.
• The timeline for filing and effectiveness of the resale registration statement (30 days and 60-90 days, respectively) is also typical for these types of transactions.

Stakeholder Impact

• Shareholders may experience dilution if the warrants are exercised.
• The company's financial position could be strengthened by the additional capital.
• Employees may benefit from the increased working capital and general corporate purposes.

Next Steps

• The holder needs to decide whether to exercise the existing warrants.
• The company needs to file the resale registration statement.
• The company needs to obtain stockholder approval for the new warrants.
• The company needs to close the transaction and receive the proceeds.

Key Dates